Lipella pharmaceuticals announces fda type c meeting for lp-10 for hemorrhagic cystitis

Pittsburgh, april 03, 2024 (globe newswire) -- lipella pharmaceuticals inc. (nasdaq: “lipo”) (“lipella,” “our,” “us” or the “company”), a clinical-stage biotechnology company addressing serious diseases with significant unmet need, today announced that the u.s. food and drug administration (“fda”) has granted a type c meeting request to discuss the company's proposed phase-2b clinical trial design for the evaluation of lp-10, an intravesical liposomal formulation of tacrolimus, as a potential treatment for moderate to severe hemorrhagic cystitis (hc). lipella expects to meet with the fda on may 21, 2024.
LIPO Ratings Summary
LIPO Quant Ranking